Evidence map›Paper›PMID 36964398›Full record

ArticleThe Journal of antibiotics2023

An efflux pump deletion mutant enabling the discovery of a macrolide as an overlooked anti-P. aeruginosa active compound.

Aoi Kimishima, Kazunari Sakai, Masako Honsho, Paul Wasuwanich, Hidehito Matsui, Yoshihiro Watanabe, Masato Iwatsuki, Toshiaki Sunazuka, Naoaki Arima, Kazutoyo Abe and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in The Journal of antibiotics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Aoi Kimishima *Graduate School of Infection Control Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan.
Kazunari Sakai *Research Management Department, Kowa Company LTD., 4-13-3 Nihonbashi-honcho, Chuo-ku, Tokyo, 103-8433, Japan.
Masako Honsho *Graduate School of Infection Control Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan.
Paul WasuwanichUniversity of Florida College of Medicine, Gainesville, FL, USA.
Hidehito MatsuiGraduate School of Infection Control Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan.ORCID 0000-0003-0099-3340
Yoshihiro WatanabeGraduate School of Infection Control Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan.ORCID 0000-0002-5756-0530
Masato IwatsukiGraduate School of Infection Control Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan.ORCID 0000-0001-8373-4314
Toshiaki SunazukaGraduate School of Infection Control Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan.
Naoaki ArimaResearch Management Department, Kowa Company LTD., 4-13-3 Nihonbashi-honcho, Chuo-ku, Tokyo, 103-8433, Japan.
Kazutoyo AbeResearch Management Department, Kowa Company LTD., 4-13-3 Nihonbashi-honcho, Chuo-ku, Tokyo, 103-8433, Japan.
Hideaki HanakiGraduate School of Infection Control Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan.
Yukihiro AsamiGraduate School of Infection Control Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan. yasami@lisci.kitasato-u.ac.jp.ORCID 0000-0003-1821-9169
Kitasato University · JPKowa (Japan) · JPKitasato Institute Hospital · JPUniversity of Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antimicrobial resistance is a serious, worldwide problem. Pseudomonas aeruginosa (P. aeruginosa) is the pathogen that poses a major threat to human health. However, resistance-nodulation-cell division type multidrug efflux pump systems defend P. aeruginosa from many antibiotics. Therefore, only limited therapeutic drugs are available. In this regard, we screened overlooked anti- P. aeruginosa compounds from the Ōmura Natural Compound library using an efflux pump deletion P. aeruginosa mutant strain, YM64, which led us to find a semisynthetic macrolide, 5-O-mycaminosyltylonolide, whose anti- P. aeruginosa activity against a standard laboratory adapted strain, PAO1, was enhanced by an efflux pump inhibitor, phenylalanine-arginine beta-naphthylamide.

Indexed as

MacrolidesPseudomonas aeruginosaAnti-Bacterial AgentsBacterial ProteinsHumansMembrane Transport ProteinsMicrobial Sensitivity TestsAnti-Bacterial AgentsBacterial ProteinsMacrolidesMembrane Transport Proteins

Identifiers

PMID36964398
OpenAlexW4360866248

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.